Seres Therapeutics, Inc. announced top-line results from an Investigator-Sponsored Trial (IST) evaluating SER-155 in 15 patients with moderate-to-severe immune checkpoint inhibitor (ICI) induced gastrointestinal inflammation (irEC). At Day 15, 80% of participants (12 of 15) achieved an immunosuppressive-free clinical response, and 33% (5 of 15) achieved complete clinical remission. Results at Day 43 showed that 33% of participants maintained an immunosuppressive-free clinical response. The company is a biotechnology company focused on developing therapeutic interventions for gastrointestinal and inflammatory and immune-related bowel diseases.
